fda compounding semaglutide news november 2025 Drugmakers battle pharmacies over compounded Ozempic and Zepbound : Shots Compounded "semaglutide" is not FDA-approved

Switching between semaglutide and tirzepatide is increasingly common, especially for researchers who have plateaued on one compound and want to explore whether a dual agonist (GLP-1/GIP) provides additional benefits

Belgium Clinical studies have found that the IGF-1 LR3 peptide exerts its effects by binding to Insulin receptors (IGF-1R) on the surface of target cells

In addition to updating its EML, the WHO is currently developing guidelines for the use of GLP-1 agonists for obesity treatment, which are slated to be released in July

3:30pm - 4:30pm Implementing weight loss into your practice and after weight loss maintenance programs